Reprogramming Immunity for Target-Specific Medicines Status: Active. Batch: YC Winter 2024. HQ: San Francisco, CA, USA. Industry: Healthcare. https://www.granzabio.com/
Details
city
San Francisco
cohort year
2024
country
United States
exited
false
industry
healthcare
one liner
Reprogramming Immunity for Target-Specific Medicines